Trial Profile
Phase I/II Study of Anti-MUC1 CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Anti-MUC1 CAR-T cell therapy (Primary)
- Indications Breast cancer; Liver cancer; Male breast cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Chemical
- 11 Jul 2016 Status changed from suspended to recruiting.
- 21 Jun 2016 Status changed from recruiting to suspended.
- 04 Nov 2015 New trial record